Search results
Showing 916 to 930 of 1808 results for nice guidelines
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Details about how accessible NICE services are and who to contact for alternative versions of information
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.
Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
NICE has developed a medtech innovation briefing (MIB) on IQoro for hiatus hernia .
Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
View recommendations for TA721Show all sections
Medical technologies evaluation programme process guide (PMG34)
Medical technologies evaluation programme process guide
Show all sections
- 1 Introduction
- 2 The medical technologies evaluation programme
- 3 Who is involved in the medical technologies evaluation programme
- 4 Identifying, selecting and routing technologies for evaluation
- 5 How medical technologies guidance is developed
- 6 Resolution
- 7 Publishing medical technologies guidance
- 8 Reviews
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Awaiting development [GID-QS10094] Expected publication date: TBC
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.